News & Press Releases

Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall care SALT LAKE CITY, Nov. 17, 2022 – More than 83% of…

IAVA and Myriad Genetics Host Live Event to Raise Awareness about Genetic Testing and Mental Health Clinical expert to share new research about treatment for veterans with depression New York,…

IAVA Partners with Myriad Genetics New Technologies for Mental Health Treatments Available New York, NY, October 31, 2022 – Iraq and Afghanistan Veterans of America (IAVA), the leading voice of the…

Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial Study showed PGx testing helps clinicians prescribe fewer medications with gene-drug…

Six in 10 of the women surveyed with depression or anxiety diagnosis say they have been ignored or dismissed by family, friends, and/or partners about their mental health concerns

SALT LAKE CITY, April 26, 2022 – Two out of three women diagnosed with depression or anxiety say they have reached or are approaching their breaking point regarding their mental health, according to the GeneSight® Mental Health Monitor, a new nationwide survey from Myriad Genetics, Inc. (NASDAQ: MYGN).

With continued commitment to innovation, company makes updates to industry-leading PGx report SALT LAKE CITY, [March 13, 2022] –Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine,…

Analysis shows combinatorial approach is more effective than single-gene testing at predicting sertraline metabolism in patients with major depressive disorder SALT LAKE CITY, Feb. 23, 2022 –Myriad Genetics, Inc. (NASDAQ:MYGN),…

SALT LAKE CITY, December 15, 2021 – Now is the time when people start to think of new year’s resolutions to improve their health. For many, the focus is on…

GeneSight Mental Health Monitor finds many parents struggle to know the difference between teenage behavior and a mental health challenge SALT LAKE CITY, [November 23, 2021] – One of the…

SALT LAKE CITY, October 11, 2021– Many Americans are experiencing anxiety symptoms as a result of the pandemic. Yet, one in five say they won’t seek treatment for mental health…

SALT LAKE CITY, September 8, 2021 – Depression medication trial and error is far too common – and may result in additional mental health challenges.

GeneSight® Mental Health Monitor finds large gap between what Americans think and what they actually know about recognizing depression. SALT LAKE CITY, July 28, 2021 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a recent nationwide poll, the GeneSight® Mental Health Monitor.

SALT LAKE CITY, April 28, 2021 – In a new nationwide poll, the GeneSight® Mental Health Monitor found that 83% of people with depression agree that life would be easier if others could understand their depression. Yet, most people who have not experienced depression may not be able to understand the challenges, including its treatment.